Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laxative-probiotic Sequential Treatment in IBS
NCT02254629Phase 1Completed
- Sponsor
- Shandong University
- Start
- Jul 2014
- Primary completion
- Aug 2015
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised trial of clostridium butyricum in irritable bowel syndrome (IBS) (3 arms), sponsored by Shandong University. Primary endpoint: Subject's Global Assessment of Relief at 8 months. Started Jul 2014; status: completed.
02
Drugs
clostridium butyricum
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT02254629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254629.